Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update


Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, will host a conference call at 8:00 a.m. ET on Thursday, August 6, 2020, to discuss financial results for the quarter ended June 30, 2020, and provide a corporate update.

The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 9297174. Due to the expected high demand on our conference provider, please plan to dial in to the call at least 15 minutes prior to the start time.

A live webcast of the conference call will also be available on the investor relations page of the company's corporate website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.


These press releases may also interest you

at 13:00
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nextdoor Holdings, Inc. (KIND)
The Law Offices of Frank R. Cruz reminds investors of the upcoming April 29, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II...

at 12:45
Sogolytics Study Examines Patient Experience Gaps in Telehealth Adoption
Leading research and experience management firm Sogolytics has released an original study examining the telehealth landscape, highlighting its achievements and challenges in providing positive experiences for patients. "It's critical for providers...

at 10:50
North America $55 Bn Dry Mix Mortar Market Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031 - ResearchAndMarkets.com
The "North America Dry Mix Mortar Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America)" report has been added to ResearchAndMarkets.com's offering....

at 09:00
Carbon Streaming Provides Update on Rimba Raya Project
Carbon Streaming Corporation (Cboe CA: NETZ) ("Carbon Streaming" or the "Company") provides an update on the Rimba Raya Project ("Rimba Raya" or the "Project"). The Company has learned of two third-party media reports that claim PT Rimba Raya...

at 09:00
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
Amgen today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1...

at 09:00
CompendiRx Unveils Innovative Approach to Long COVID: Empowering Patients Worldwide
The latest data from the US Census Bureau reflects alarming statistics from those who have had COVID-19: 32.4% of adults aged 40-49 and 28.8% of those aged 30-39 report ever experiencing long COVID, grappling with debilitating symptoms such as...

More news about Covid-19 virus...


News published on and distributed by: